{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+%28NSCLC%29&page=6", "query": { "condition": "Non-small Cell Lung (NSCLC)", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3564, "total_pages": 357, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+%28NSCLC%29&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+%28NSCLC%29&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T23:17:41.103Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05746481", "title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Liza Villaruz, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-08-10", "completion_date": "2025-11-08", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05746481" }, { "nct_id": "NCT04254107", "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Carcinoma", "Gastroesophageal Junction Carcinoma", "Classical Hodgkin Lymphoma", "Diffuse Large B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Cutaneous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "Cervical Cancer" ], "interventions": [ { "name": "SEA-TGT", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" }, { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2020-05-29", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254107" }, { "nct_id": "NCT00082472", "title": "Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Doxorubicin HCl Inhalation Solution", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zivena", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-04-18", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "The Bronx", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082472" }, { "nct_id": "NCT03968419", "title": "This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-11-05", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 4, "location_summary": "La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Syracuse", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03968419" }, { "nct_id": "NCT07063745", "title": "A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer With MTAP Deletion" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-01-02", "completion_date": "2031-08-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 44, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063745" }, { "nct_id": "NCT00520845", "title": "Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2007-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520845" }, { "nct_id": "NCT00367601", "title": "Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nasser Hanna, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2016-02-11", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 13, "location_summary": "Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00367601" }, { "nct_id": "NCT00769600", "title": "Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 23, "start_date": "2008-11", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769600" }, { "nct_id": "NCT04430712", "title": "Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-08-01", "completion_date": "2022-08-22", "has_results": false, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430712" }, { "nct_id": "NCT02637531", "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors (Part A/B/C/D)", "Non-small Cell Lung Cancer (Part E)", "Melanoma (Part E)", "Squamous Cell Cancer of the Head and Neck (Part E)", "Triple Negative Breast Cancer (Part F)", "Adrenocortical Carcinoma (Part G)", "Mesothelioma (Part G)", "High-circulating Myeloid-derived Suppressor Cells (Part H)" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2015-12", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-10-22T23:17:41.103Z", "location_count": 11, "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02637531" } ] }